Benatti Luca - Jun 4, 2025 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ Brendan Hannah as attorney-in-fact for Luca Benatti
Stock symbol
QNCX
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 05:38 PM
Previous filing
Jun 7, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Benatti Luca Director C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO /s/ Brendan Hannah as attorney-in-fact for Luca Benatti 2025-06-06 0001613842

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Director Stock Option (Right to Buy) Award $0 +27K $0.00 27K Jun 4, 2025 Common Stock 27K $1.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.